Please select an option below to help us tailor your newsletter to best suit your content interests!
Exciting News Cryoablation, a groundbreaking treatment for early-stage breast cancer, is proving to be a game-changer for older women! Our very own Dr. Richard Fine presented remarkable findings at The American Society of Breast Surgeons annual meeting. Â KEY HIGHLIGHTS: Study Results: After a 5-year follow-up, the study showed a low ipsilateral breast tumor recurrence rate… Read more »
Dr. Jason Porter details groundbreaking research for KRAS-mutant NSCLC during a Targeted Oncology Community Case Forum. 🎉 Explore the CodeBreaK 100 and CodeBreaK 200 studies, showing promising results and insights into new treatment strategies. Read more about the accelerated approval of new treatment options, and their impact on patients’ lives. Let’s revolutionize #LungCancer care together!… Read more »
Tuesday, September 19 at 5pm EST Join Dr. Jason Porter for a live, dynamic discussion about the critical role of biomarker testing and clinical trials in lung cancer! Dr. Porter will partner with Estelamari Rodriguez, MD, MPH from the University of Miami’s Sylvester Comprehensive Cancer Center and moderator Terric Conneran, Founder of KRAS Kickers, to… Read more »
Dr. Noam VanderWalde, one of our incredible Radiation Oncologists here at West, is extremely passionate about geriatric oncology care. Below is a link to his most recent cooperative group publication, entitled “Disparities in older adult accrual to cancer trials: Analysis from the alliance for clinical trials in oncology (A151736).” Click the link below to read… Read more »
West Cancer Center, Memphis, Tennessee; City of Hope Comprehensive Cancer Center, Duarte, California; Mays Cancer Center, home to UT Health San Antonio MD Anderson, San Antonio, Texas; O’Neal Comprehensive Cancer Center, and University of Alabama at Birmingham, Birmingham, Alabama; comprise the new Advancing Inclusive Research® Site Alliance. This coalition of clinical research sites aims to advance the representation… Read more »
Dr. Daniel Vaena, Director of Experimental Therapeutics Program at West Cancer Center Research Institute, co-presented updated data from Compugen Ltd.’s Phase 1 dose escalation and expansion study of COM701 as a monotherapy, and in a dose escalation combination study with Opdivo® (nivolumab) Vaena states “Although these results are very preliminary, they suggest that targeting… Read more »
Axel Grothey, MD, medical oncologist and our Director of Gastrointestinal Cancer Research, discusses the role of precision medicine in colorectal cancer (CRC) with OncLive. Grothey says, “With the rise of molecular profiling, the field of CRC has shifted away from a one-size-fits-all approach and entered an era of precision medicine. Notably, molecular profiling guides the… Read more »
Lee S. Schwartzberg, MD, of the West Cancer Center, discusses phase III results from the CONTESSA study, which showed that an all-oral regimen of tesetaxel plus a reduced dose of capecitabine significantly improved progression-free survival compared with capecitabine alone in patients with HER2-negative, hormone receptor–positive metastatic breast cancer previously treated with a taxane (Abstract GS4-01)…. Read more »
Matching patient populations with a targetable genomic alteration to a specific investigational study is the aim of a new clinical trial through OneR and Genentech. This partnership will facilitate collaborations on various clinical trials, scientific research and real-world data studies that will advance personalized cancer care at community oncology centers like West. “With too many… Read more »